93 related articles for article (PubMed ID: 23897164)
1. Functional influence of human CYP2D6 allelic variations: P34S, E418K, S486T, and R296C.
Kim J; Lim YR; Han S; Han JS; Chun YJ; Yun CH; Lee CH; Kim D
Arch Pharm Res; 2013 Dec; 36(12):1500-6. PubMed ID: 23897164
[TBL] [Abstract][Full Text] [Related]
2. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
4. Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae.
Tsuzuki D; Takemi C; Yamamoto S; Tamagake K; Imaoka S; Funae Y; Kataoka H; Shinoda S; Narimatsu S
Pharmacogenetics; 2001 Nov; 11(8):709-18. PubMed ID: 11692080
[TBL] [Abstract][Full Text] [Related]
5. Effects of G169R and P34S substitutions produced by mutations of CYP2D6*14 on the functional properties of CYP2D6 expressed in V79 cells.
Shiraishi T; Hosokawa M; Kobayashi K; Tainaka H; Yamaura Y; Taguchi M; Chiba K
Drug Metab Dispos; 2002 Nov; 30(11):1201-5. PubMed ID: 12386125
[TBL] [Abstract][Full Text] [Related]
6. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
7. Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Drug Metab Bioanal Lett; 2022; 15(1):51-63. PubMed ID: 35049443
[TBL] [Abstract][Full Text] [Related]
8. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese.
Wang SL; Lai MD; Huang JD
Drug Metab Dispos; 1999 Mar; 27(3):385-8. PubMed ID: 10064570
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
12. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
Oscarson M; Hidestrand M; Johansson I; Ingelman-Sundberg M
Mol Pharmacol; 1997 Dec; 52(6):1034-40. PubMed ID: 9415713
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).
Han S; Choi S; Chun YJ; Yun CH; Lee CH; Shin HJ; Na HS; Chung MW; Kim D
Biol Pharm Bull; 2012; 35(3):394-9. PubMed ID: 22382327
[TBL] [Abstract][Full Text] [Related]
15. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
[TBL] [Abstract][Full Text] [Related]
16. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.
Huang J; Chuang SK; Cheng CL; Lai ML
Clin Pharmacol Ther; 1999 Apr; 65(4):402-7. PubMed ID: 10223777
[TBL] [Abstract][Full Text] [Related]
18. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
[TBL] [Abstract][Full Text] [Related]
19. Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A2*8, *15, and *16 (R456H, P42R, and R377Q).
Lim YR; Kim IH; Han S; Park HG; Ko MJ; Chun YJ; Yun CH; Kim D
Biomol Ther (Seoul); 2015 Mar; 23(2):189-94. PubMed ID: 25767688
[TBL] [Abstract][Full Text] [Related]
20. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
